MA41941A - Procédé de purification de protéines - Google Patents

Procédé de purification de protéines

Info

Publication number
MA41941A
MA41941A MA041941A MA41941A MA41941A MA 41941 A MA41941 A MA 41941A MA 041941 A MA041941 A MA 041941A MA 41941 A MA41941 A MA 41941A MA 41941 A MA41941 A MA 41941A
Authority
MA
Morocco
Prior art keywords
purification process
protein purification
protein
purification
Prior art date
Application number
MA041941A
Other languages
English (en)
Inventor
Sam Philip Heywood
Gavin Barry Wild
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MA41941A publication Critical patent/MA41941A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624Disulfide-stabilized antibody (dsFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA041941A 2015-04-22 2016-04-20 Procédé de purification de protéines MA41941A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1506868.7A GB201506868D0 (en) 2015-04-22 2015-04-22 Method for protein purification

Publications (1)

Publication Number Publication Date
MA41941A true MA41941A (fr) 2018-02-28

Family

ID=53299017

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041941A MA41941A (fr) 2015-04-22 2016-04-20 Procédé de purification de protéines

Country Status (19)

Country Link
US (2) US10927164B2 (fr)
EP (1) EP3286205A1 (fr)
JP (2) JP6866300B2 (fr)
KR (1) KR102675400B1 (fr)
CN (1) CN107636012B (fr)
AR (1) AR104358A1 (fr)
AU (1) AU2016251223B2 (fr)
BR (1) BR112017022073A2 (fr)
CA (1) CA2983057C (fr)
CL (1) CL2017002614A1 (fr)
CO (1) CO2017010631A2 (fr)
EA (1) EA201792328A1 (fr)
GB (1) GB201506868D0 (fr)
IL (1) IL254883B (fr)
MA (1) MA41941A (fr)
MX (1) MX392543B (fr)
MY (1) MY189854A (fr)
SG (1) SG11201708256YA (fr)
WO (1) WO2016169992A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013081540A1 (fr) * 2011-11-30 2013-06-06 Ge Healthcare Bio-Sciences Ab Matrice de chromatographie par affinité
GB201506868D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
CN108085358A (zh) * 2018-02-08 2018-05-29 保定冀中药业有限公司 一种犬细小病毒单克隆抗体IgG2b-Fab片段的制备方法
US12296285B2 (en) * 2019-08-02 2025-05-13 UCB Biopharma SRL Methods for purifying antibodies
GB201919058D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
BR112022011993A2 (pt) * 2019-12-26 2022-09-20 Abl Bio Inc Método para purificar peptídeo biologicamente ativo usando cromatografia de afinidade de proteína a
GB202109246D0 (en) * 2021-06-28 2021-08-11 Cytiva Bioprocess R & D Ab A method of separating bispecific antibodies
WO2025248017A1 (fr) * 2024-05-31 2025-12-04 UCB Biopharma SRL Procédé de purification de protéines de recombinaison

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
CA2374013A1 (fr) * 1999-05-15 2000-11-23 University Of California, San Diego Domaines avec activites voulues fondes sur la proteine a
CA2433227A1 (fr) * 2000-12-29 2002-08-01 Bio-Technology General, Inc. Anticorps humains specifiques pour la therapie selective du cancer
EP1614693A4 (fr) * 2003-03-31 2006-07-19 Kirin Brewery Purification d'un anticorps monoclonal humain et d'un anticorps polyclonal humain
AU2009282234A1 (en) 2008-08-14 2010-02-18 Merck Sharp & Dohme Corp. Methods for purifying antibodies using protein a affinity chromatography
EP2398498B1 (fr) 2009-02-17 2018-09-05 UCB Biopharma SPRL Molécules d'anticorps ayant une spécificité pour ox40 humain
MX2013004720A (es) * 2010-11-01 2013-05-28 Dsm Ip Assets Bv Purificacion de anticuerpos mediante cromatografia de intercambio ionico de una uncia unidad.
EP2646126A4 (fr) 2010-11-29 2014-12-17 Ge Healthcare Bio Sciences Ab Matrice de chromatographie d'affinité
SI2776466T1 (sl) 2011-11-11 2017-12-29 Ucb Biopharma Sprl Protitelesa, ki se vežejo na albumin in njihovi vezavni fragmenti
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
MX2014009565A (es) * 2012-02-10 2014-11-10 Genentech Inc Anticuerpos monocatenarios y otros heteromultimeros.
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
EP3066133A1 (fr) * 2013-11-04 2016-09-14 Glenmark Pharmaceuticals S.A. Production de cellules t reciblant des immunoglobulines héréro-dimériques
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506868D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method

Also Published As

Publication number Publication date
CL2017002614A1 (es) 2018-04-27
US12516106B2 (en) 2026-01-06
MX2017013333A (es) 2018-02-19
AU2016251223A1 (en) 2017-10-26
US20210171609A1 (en) 2021-06-10
US10927164B2 (en) 2021-02-23
CN107636012A (zh) 2018-01-26
JP2021066734A (ja) 2021-04-30
IL254883B (en) 2021-09-30
WO2016169992A1 (fr) 2016-10-27
GB201506868D0 (en) 2015-06-03
BR112017022073A2 (pt) 2018-08-14
AR104358A1 (es) 2017-07-12
KR102675400B1 (ko) 2024-06-13
CA2983057A1 (fr) 2016-10-27
EA201792328A1 (ru) 2018-05-31
JP6866300B2 (ja) 2021-04-28
EP3286205A1 (fr) 2018-02-28
SG11201708256YA (en) 2017-11-29
JP2018520089A (ja) 2018-07-26
IL254883A0 (en) 2017-12-31
KR20170139131A (ko) 2017-12-18
AU2016251223B2 (en) 2021-12-09
MY189854A (en) 2022-03-14
MX392543B (es) 2025-03-19
CO2017010631A2 (es) 2018-01-05
CA2983057C (fr) 2025-05-06
US20180100007A1 (en) 2018-04-12
CN107636012B (zh) 2022-08-02

Similar Documents

Publication Publication Date Title
EP3564866A4 (fr) Procédé de calcul
EP3392266A4 (fr) Procédé de synthèse de linaclotide
MA41941A (fr) Procédé de purification de protéines
EP3718462A4 (fr) Procédé de détection
EP3004135A4 (fr) Procédé de purification de protéine
DK3341479T3 (da) LNA-G-Proces
EP3412623A4 (fr) Procédé de purification
DK3416974T3 (da) Proteinoprensning
HUE057118T2 (hu) Folyamat
EP3521299A4 (fr) Procédé de purification de protéine recombinée
EP2975020A4 (fr) Procédé de purification de 1,5-diaminopentane
EP3505263A4 (fr) Procédé de purification de sol souterrain
EP3380628A4 (fr) Procédé de broyage
EP3265120C0 (fr) Procédé
PT3256546T (pt) Processo de despolimerização
MA43944A (fr) Procédé de purification de liquide
EP3318552A4 (fr) Procédé de purification de méthionine
EP3626804A4 (fr) Procédé de purification de raffinat-2
EP2970857A4 (fr) Nouveau procédé de purification protéique
EP3333571A4 (fr) Procédé de quantification parallèle de variant de protéine
MA46454A (fr) Procédé multi-protéase
EP3404037A4 (fr) Procédé de purification de fibrinogène
SG11201802755WA (en) Process for purification of methyl methacrylate
EP3697821A4 (fr) Procédé
DK3237433T3 (da) Fremgangsmåde til fremstilling af protein